Dare Bioscience (DARE) Liabilities and Shareholders Equity (2013 - 2026)

Dare Bioscience (DARE) has 13 years of Liabilities and Shareholders Equity data on file, last reported at $32.5 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 46.94% year-over-year to $32.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $94.8 million (up 23.5% YoY) and the FY2025 annual result came in at $32.5 million, up 46.94% from the prior year.
• Liabilities and Shareholders Equity improved to $32.5 million in Q4 2025, from $30.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $55.8 million in Q4 2021 to a low of $10.5 million in Q1 2021.
• A 5-year average of $29.8 million and a median of $24.3 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity jumped 639.1% — and 2024, when it plunged 57.15%.
• Tracing DARE's Liabilities and Shareholders Equity over 5 years: stood at $55.8 million in 2021, then decreased by 21.47% to $43.8 million in 2022, then tumbled by 51.44% to $21.3 million in 2023, then advanced by 3.85% to $22.1 million in 2024, then surged by 46.94% to $32.5 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $32.5 million (Q4 2025), $30.7 million (Q3 2025), and $13.0 million (Q2 2025), per Business Quant data.